This HTML5 document contains 44 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB03424/identifier/pubchem-substance/
n13http://linked.opendata.cz/resource/drugbank/drug/DB03424/identifier/drugbank/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n14http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/drugbank/drug/DB03424/identifier/bindingdb/
n10http://linked.opendata.cz/resource/drugbank/drug/DB03424/identifier/pdb/
n11http://linked.opendata.cz/resource/drugbank/drug/DB03424/identifier/pubchem-compound/

Statements

Subject Item
n2:DB03424
rdf:type
n3:Drug
n3:description
Bestatin is a competitive protease inhibitor. It is an inhibitor of aminopeptidase B, leukotriene A4 hydrolase, aminopeptidase N. It is being studied for use in the treatment of acute myelocytic leukemia.
n3:generalReferences
# Scornik OA, Botbol V: Bestatin as an experimental tool in mammals. Curr Drug Metab. 2001 Mar;2(1):67-85. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11465152 # Yoneda J, Saiki I, Fujii H, Abe F, Kojima Y, Azuma I: Inhibition of tumor invasion and extracellular matrix degradation by ubenimex (bestatin). Clin Exp Metastasis. 1992 Jan;10(1):49-59. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1733647 # Bauvois B, Dauzonne D: Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects. Med Res Rev. 2006 Jan;26(1):88-130. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16216010 # Wickstrom M, Larsson R, Nygren P, Gullbo J: Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Sci. 2011 Mar;102(3):501-8. doi: 10.1111/j.1349-7006.2010.01826.x. Epub 2011 Jan 30. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21205077
n3:group
experimental
n3:indication
An adjuvant therapy used for acute and chronic myelonous leukemia, lung cancer and nasopharyngeal cancer. It is also used to treat hypercholesterolaemia.
owl:sameAs
n7:DB03424 n14:DB03424
dcterms:title
Bestatin
adms:identifier
n9:46505598 n10:BES n11:439299 n12:23971 n13:DB03424
n3:synonym
Ubenimex
n3:synthesisReference
Hamao Umezawa, Takaaki Aoyagi, Tomio Takeuchi, Masa Hamada, Yoshiro Okami, "Biologically active substance, bestatin, and production thereof." U.S. Patent US4052449, issued October 04, 1977.
n3:IUPAC-Name
n4:271B46E4-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B46EA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B46E9-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B46E6-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B46E7-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B46E8-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B46E2-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B46E0-363D-11E5-9242-09173F13E4C5 n4:271B46E3-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B46E1-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B46F0-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B46F1-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B46EB-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B46EC-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B46EE-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B46ED-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B46EF-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
58970-76-6
n3:category
n3:Bioavailability
n4:271B46F6-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B46F8-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B46F9-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B46F5-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B46F4-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B46F7-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B46E5-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B46F2-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B46F3-363D-11E5-9242-09173F13E4C5